SAAmplify™-ɑSYN Biomarker Test (CSF)

The SAAmplify-ɑSYN Test (formerly SYNTap) helps physicians diagnose synucleinopathies such as: Parkinson’s, DLB, Alzheimer’s with Lewy bodies, MCI, and MSA.

Enabling precision medicine for neurodegenerative disorders

This website is intended for the informational purposes of healthcare professionals.

Scientist working at the laboratory

Parkinson’s Disease

How the SAAmplify-ɑSYN Test helps improve diagnostic accuracy for various types of Parkinson's.

Lewy Body Dementia

How the SAAmplify-ɑSYN Test can improve the diagnostic challenges of Lewy body dementia.

Doctor and patient

AD with Lewy Bodies

How the SAAmplify-ɑSYN Test helps differentiate the Alzheimer's variant: AD with Lewy bodies.

Multiple System Atrophy

How the SAAmplify-ɑSYN Test helps physicians differentiate MSA from Parkinson's disease.

Scientist working with chemicals in laboratory

MCI with Lewy Bodies

How the SAAmplify-ɑSYN Test helps detect Minimal Cognitive Impairment with Lewy bodies early.

Download Spec. Sheet

Details on the SAAmplify-ɑSYN Test performance characteristics.

Amprion's scientist, Luis Concha discovering an ultra sensitive prion detection

Explore Our Science

A pioneer of prion detection science, Amprion innovates biomarker testing to accurately detect misfolded proteins associated with brain diseases.

After decades of research, Amprion is thrilled to roll out its impactful discoveries from the lab to the world. 

Amprion Announces

Our flagship α-synuclein SAA, SYNTap®, is getting a makeover.

Effective September 9, 2024, SYNTap will be 

And stay tuned for the SAAmplify family of panels, coming soon!